RecallRadar

FDA Drug recall D-0452-2025

Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limit…

On 2025-06-04 the FDA classified a Class II recall of Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limit… by Glenmark Pharmaceuticals Usa, citing OOS results reported for the Dissolution (by UV) test.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0452-2025
ClassificationClass II
Statusongoing
Initiated2025-05-15
Published2025-06-04
Last updated2026-09-13 11:52 UTC
CompanyGlenmark Pharmaceuticals Usa
DistributionUS

Product

Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited. Colvale-Bardez, Goa - 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-356-01

Reason

OOS results reported for the Dissolution (by UV) test.

Identifiers

ndc68462-380-01
ndc68462-380-05
ndc68462-356-01
ndc68462-356-05
code_infoLots: 19234121, 19234148, Exp Sep-30-25; Lots 19242881, 19242899, Exp Jun-30-26

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0452-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.